StabiLux Biosciences Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$554K
- Investors
-
11
StabiLux Biosciences General Information
Description
Developer of high-brightness fluorophores designed for biomedical researchers to detect rare biomarkers. The company's technology offers proprietary dyes with tunable brightness, antibody conjugation, photostability, water solubility, and multi-color channel compatibility, enabling biomedical researchers to identify rare events and viruses with increased sensitivity using existing flow cytometry equipment.
Contact Information
Website
www.stabilux-biosciences.comCorporate Office
- 600 South Wagner Road
- Ann Arbor, MI 48103
- United States
Corporate Office
- 600 South Wagner Road
- Ann Arbor, MI 48103
- United States
StabiLux Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 16-May-2024 | $554K | Completed | Generating Revenue | ||
| 9. Later Stage VC | 01-Apr-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 19-Mar-2021 | Completed | Product In Beta Test | |||
| 7. Grant | 02-Sep-2020 | Completed | Startup | |||
| 6. Later Stage VC | 12-May-2020 | Completed | Startup | |||
| 5. Later Stage VC | 01-Apr-2020 | Completed | Startup | |||
| 4. Seed Round | 29-Sep-2017 | Completed | Startup | |||
| 3. Grant | 15-Sep-2017 | Completed | Startup | |||
| 2. Grant | 31-Dec-2016 | $241K | Completed | Startup | ||
| 1. Grant | 01-Jul-2015 | $225K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
StabiLux Biosciences Signals
StabiLux Biosciences Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ann Arbor SPARK | Accelerator/Incubator | Minority | ||
| John Lilly Strategic Insights | Corporation | Minority | ||
| Lateral Capital Management | Venture Capital | Minority | ||
| Alligator Holdings | Venture Capital | Minority | ||
| Invest Detroit Ventures | Corporate Venture Capital | Minority |
StabiLux Biosciences FAQs
-
When was StabiLux Biosciences founded?
StabiLux Biosciences was founded in 2014.
-
Where is StabiLux Biosciences headquartered?
StabiLux Biosciences is headquartered in Ann Arbor, MI.
-
What is the size of StabiLux Biosciences?
StabiLux Biosciences has 10 total employees.
-
What industry is StabiLux Biosciences in?
StabiLux Biosciences’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is StabiLux Biosciences a private or public company?
StabiLux Biosciences is a Private company.
-
What is StabiLux Biosciences’s current revenue?
The current revenue for StabiLux Biosciences is .
-
How much funding has StabiLux Biosciences raised over time?
StabiLux Biosciences has raised $1.85M.
-
Who are StabiLux Biosciences’s investors?
Ann Arbor SPARK, John Lilly Strategic Insights, Lateral Capital Management, Alligator Holdings, and Invest Detroit Ventures are 5 of 11 investors who have invested in StabiLux Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process